Implementing Clinical Pharmacogenetics: Point-of-Care and Pre-Emptive Testing

Stuart A. Scott

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Although the field of pharmacogenetics was established over 50. years ago, clinical testing for germline pharmacogenetic variants implicated in interindividual drug response variability has only recently become available to help physicians guide pharmacotherapy. However, despite robust pharmacogenetic associations with medication efficacy and/or adverse effects, physician adoption of clinical pharmacogenetic testing has not been widespread. This is likely due to a number of factors including a lack of professional education and practice guidelines, concerns over clinical utility, regulatory and reimbursement issues, and the feasibility of integrating rapid turnaround-time genetic testing into routine clinical practice. To address the specific challenge of testing feasibility and turnaround time, both point-of-care and pre-emptive pharmacogenetic testing programs have recently been deployed in selected clinical contexts and academic centers. This chapter aims to review pharmacogenetic testing implementation with a focus on the germline genetic variants that are implicated in drug response variability and their use at the point of care.

Original languageEnglish
Title of host publicationHandbook of Pharmacogenomics and Stratified Medicine
PublisherElsevier Inc.
Number of pages10
ISBN (Electronic)9780123868831
ISBN (Print)9780123868824
StatePublished - 6 May 2014


  • Clinical genetics
  • Genetic testing
  • Molecular genetics
  • Personalized medicine
  • Pharmacogenetics
  • Pharmacogenomics
  • Point-of-care testing
  • Pre-emptive testing


Dive into the research topics of 'Implementing Clinical Pharmacogenetics: Point-of-Care and Pre-Emptive Testing'. Together they form a unique fingerprint.

Cite this